This company listing is no longer active
AXNX * Stock Overview
A medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Axonics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,227.00 |
| 52 Week High | US$1,227.00 |
| 52 Week Low | US$1,227.00 |
| Beta | 0.82 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXNX * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how AXNX * performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how AXNX * performed against the MX Market.
Price Volatility
| AXNX * volatility | |
|---|---|
| AXNX * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: AXNX *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine AXNX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 797 | Ray Cohen | www.axonics.com |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.
Axonics, Inc. Fundamentals Summary
| AXNX * fundamental statistics | |
|---|---|
| Market cap | Mex$72.17b |
| Earnings (TTM) | -Mex$34.36m |
| Revenue (TTM) | Mex$8.21b |
8.8x
P/S Ratio-2,101x
P/E RatioIs AXNX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXNX * income statement (TTM) | |
|---|---|
| Revenue | US$408.81m |
| Cost of Revenue | US$98.55m |
| Gross Profit | US$310.26m |
| Other Expenses | US$311.97m |
| Earnings | -US$1.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 75.89% |
| Net Profit Margin | -0.42% |
| Debt/Equity Ratio | 0% |
How did AXNX * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/06 18:36 |
| End of Day Share Price | 2024/08/09 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Axonics, Inc. is covered by 9 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | Barclays |
| Travis Steed | BofA Global Research |
| Christopher Pasquale | Guggenheim Securities, LLC |